Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Investor Presentation (2000)
22 slides from Getinge Ab Class B's investor presentation, 2000
Slide 1: GETINGE
GETINGE An expanding Medical-Technology group with focus on comprehensive solutions for infection control and care of elderly and disabled people Customers Acute Care Long term care and Industry Net Sales 4 900 million SEK Associates 3 800 Manufacturing 17 production units in 8 countries Distributio
Slide 2: Business Scope
Business Scope Infection Control Extended Care Business Areas Sterilisation Hygiene systems Patient handling Disinfection Antidecubitus 55 % 45 % Customer segments Industry Acute care Long term care I5 % 40 % 45 %
Slide 3: Market Development
Market Development 2000 Total Long term care Acute care Industry 49 % 60 % 44 % 45 % Western Europe 41 % 37 % 40 % 40 % North America 6 % 2% 10 % 7% Asia, Australia 4 % 1% 6% 8% ROW
Slide 4: Extended Care
Extended Care Hygiene Anti Patient Systems decubitus Handling Complete solutions for institutional extended care: Nursing Homes, Hospitals, Assisted Living
Slide 5: Extended Care
Extended Care Hygiene SystemsPatient Handling Antidecubitus Market 1 400 MSEK 1 700 MSEK 8 000 MSEK Growth 5 - 7 % 10 % 10 % Getinge Getinge Hillrom US Sakai JP Sunrise US KNCI US Chiltern UK Liko SE Huntleigh UK Guldman DK Getinge
Slide 6: Extended Care - Growth Opportunities
Extended Care Growth Opportunities Market Market Market Assistive Anti- size* growth*shares* equipment decubitus Hospital 400 ? 45 % Growth Penetrate Nursing Homes 2000 5% 50 % Consolid Growth Assisted Living 900 10 % 25 % Growth - Home Care 2700 7% - - - *) Assistive equipment
Slide 7: Extended Care - Strategic Corner-Stones
Extended Care Strategic Corner-Stones Product Complete leadership Solutions Positive outcomes
Slide 8: Extended Care - Highlights
Extended Care - Highlights Strong product Pipeline New range of institutional lifters Ceiling hoists - Techno-Médic Assisted living - Own development & Parker Bath Efficient Distribution New sales and marketing organisation Improves market penetration / reduced cost Sourcing Transfer supplier base t
Slide 9: Extended Care - Orders received
Extended Care Orders received (MSEK) 2000 1999 Change 2000 1999 Change per market Q3 Q3 9m 9m USA and Canada 188 170 11% 556 577 -4% Great Britain 137 109 26% 398 379 5% Germany 59 59 0% 177 177 0% Other W. Europe 107 99 8% 319 299 7% Rest of the world 27 16 74% 61 56 7% 517 452 14% 1 510 1 489 1% p
Slide 10: Extended Care - Results
Extended Care Results (MSEK) 2000 1999 2000 1999 1999 Q3 Q3 9m 9m FY Net sales 499 441 1 477 1 493 2 008 Gross profit % 48.5% 49.9% 49.3% 52.3% 52.4% Operating cost -174 -173 -521 -549 -731 Operating profit 67 48 208 232 320 Operating margin% 13.5% 10.8% 14.1% 15.5% 16.0%
Slide 11: Infection Control - Health Care
nfection Control - Health Care Disinfection SterilizationIT-solutions Load handling Complete Systems for: Central Processing Departments, Outpatient Surgery, Wards, Infectious Waste, Microbiology, Pharmacies
Slide 12: Infection Control - Industry
Infection Control - Industry SterilizationWashi Water Load ng Treatment Handling Complete Systems for: Production, Research / Laboratories, Animal Care Facilities, Food Industry
Slide 13: Infection Control
Infection Control Sterilization Disinfection Market 6200 MSEK 2500 MSEK Growth 5-7% 5-7% Getinge Getinge Steris US Miele DE Sakura JP Steris US J & J US Meiko DE MMM DE Bellimed CH Fedegari IT
Slide 14: Infection Control Health Care - From Product to Solution
Infection Control Health Care From Product to Solution Steriliser Disinfector Load handling Complete Logistics Infection Information management Control Consumables After Sales service Solutions Education From Cost to Revenue
Slide 15: Infection Control - Strategic Corner-Stones
Infection Control Strategic Corner-Stones Cost leadership Complete Solutions Service Infrastructure
Slide 16: Infection Control - Highlights
Infection Control - Highlights Improved production structure Expand After Sales revenue Evaluate Service provider concept Growth opportunities in Life Science and Long Term Care sector
Slide 17: Infection Control - Orders received
Infection Control Orders received MSEK 2000 1999 Change 2000 1999 Change per market Q3 Q3 9m 9m Western Europe 267 303 -12% 919 980 -6% USA and Canada 333 256 30% 945 815 16% Asia/Australia 83 143 -42% 206 243 -15% Rest of the world 50 49 2% 158 92 73% Business area total 732 750 -3% 2 228 2 129 5%
Slide 18: Infection Control - Results
Infection Control Results (MSEK) 2000 1999 2000 1999 1999 Q3 Q3 9m 9m FY Net sales 687 621 2 097 1 916 2 811 Gross profit % 33.9% 36.8% 36.0% 38.2% 38.6% Operating cost -184 -167 -549 -517 -719 Operating profit 49 61 207 216 365 Operating margin% 7.2% 9.9% 9.9% 11.2% 13.0%
Slide 19: Getinge Financial Objectives
Getinge Financial Objectives To hold world leading position in prioritised business segments (No 1 & No 2) To increase P B T by 15% P.A. over a business cycle through a combination of internal and external growth Internally generated cash flow to sustain an external growth rate of 7-8%
Slide 20: Getinge Industrier - Results
Getinge Industrier Results (MSEK) 2000 1999 Change 2000 1999 Change 1999 Q3 Q3 9m 9m FY Orders received 1 264 1 216 4% 3 783 3 664 3% 4 932 Net sales 1 201 1 075 12% 3 620 3 456 5% 4 885 Operating profit 118 110 7% 419 452 -7% 692 Operating margin 9.8% 10.2% -0.4% 11.6% 13.1% -1.5% 14.2% Profit befo
Slide 21: Balance Sheets (MSEK)
Balance Sheets (MSEK) Assets 2000-09-30 1999-09-30 1999-12-31 Goodwill 1 103 999 1 013 Fixed assets 1 036 719 816 Stock-in-trade 907 825 765 Receivables 1 695 1 516 1 625 Liquid assets 268 204 159 Total Assets 5 010 4 263 4 378 Shareholders' equity & Liabilities Shareholders' equity 1 714 1 372 1 56
Slide 22: Growth by acquisition
Growth by acquisition Existing Business Areas Acquisitions additional products New markets / Economies Priority: Antidecubitus Establish a third Business Area